Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PersoMed-I: Personalized Risk-Adapted Therapy in Post-Pubertal Medulloblastoma
2023-506193-12-00Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of sonidegib, lomustine, vincristine and cisplatin in medulloblastoma and medulloblastoma WNT activated (WNT-MB) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival (PFS) by central review in SHH-activated subgroup. Started Jul 2024; status: completed.
02
Drugs
sonidegiblomustinevincristinecisplatin
03
Conditions
medulloblastomamedulloblastoma WNT activated (WNT-MB)
Beyond the preview
Go deeper on 2023-506193-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506193-12-00.